Related Experiment Video

Updated: Aug 15, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[Anticoagulation for secondary prevention: which drug in which situation?]

J Weil1, H Schunkert

  • 1Medizinische Klinik II, Universität Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck. joachim.weil@innere2.uni-luebeck.de

Der Internist
|October 19, 2005
PubMed

Insights

New direct thrombin inhibitors show promise for preventing blood clots in cardiovascular disease patients. Careful consideration of individual bleeding risks is crucial when deciding on anticoagulation and antiplatelet therapies.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Context:

  • Thromboembolic events are a significant complication in cardiovascular diseases.
  • Current secondary prevention strategies include heparin and vitamin-K antagonists.
  • Atherothrombosis management relies heavily on antiplatelet therapy, with aspirin as a traditional option.

Purpose:

  • To review the role of anticoagulation and antiplatelet therapies in the secondary prevention of thromboembolic complications.
  • To discuss the emerging class of direct thrombin inhibitors and their efficacy.
  • To highlight the importance of balancing therapeutic benefits against bleeding risks.

Summary:

  • Direct thrombin inhibitors are a new class of anticoagulants demonstrating comparable efficacy to existing agents for venous thromboembolism prophylaxis.
  • The clinical utility of direct thrombin inhibitors in secondary prevention requires further evaluation through ongoing trials.
  • Thienopyridines and glycoprotein IIb/IIIa inhibitors have expanded antiplatelet treatment options for atherothrombotic diseases.
  • The decision to use anticoagulation and antiplatelet therapy must be individualized based on a patient's benefit-risk ratio, particularly concerning bleeding risk.

Impact:

  • Provides an overview of current and emerging therapeutic options for thromboembolic event prevention.
  • Emphasizes the critical need for personalized medicine in managing cardiovascular thrombotic disorders.
  • Informs clinical decision-making regarding the use of anticoagulants and antiplatelet agents.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...